U.S. Markets open in 4 hrs 26 mins

Repros Therapeutics Inc. (RPRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.57+0.02 (+3.33%)
At close: 4:00PM EDT
People also watch
  • After studying the results compiled in this new 16 year combined study on secondary hypo, diet and exercise, I've gone back and compared to what Rprx reported in the 6 month period of their latest clinical trial. The results from both studies almost mirror each other and 2 points of interest become increasingly important. The first is while diet and exercise does modestly increase total T levels, it does very little to increase free T levels, which is where all the benefits lie. So in the end, if a man is not increasing free T levels, then total T has very little meaning. In the Rprx study, total T on diet and exercise increased 105 ng/dl, from 263 to 368. But when looking at free T, levels only increased 1.5 pg/ml, from 55.6 to 57.1. When Enclomiphene was adding to diet an exercise, total T went from 277 to 780, but most importantly free T went from 56.3 to 140.1, p=0.0001. Clearly this demonstrates that without Enclomiphene, diet and exercise is not enough to relieve symptoms or reverse disorder .
    The second important result from both studies was on weight loss. While both studies show that diet and exercise resulted in weight loss, only when T levels are elevated did men in the studies convert fat mass to lean mass. In the Rprx study although placebo men lost more weight, their lean mass decreased 0.3 kg while Enclomiphene men showed a 1.4 kg increase.
    Hopefully these 2 important results, along with improvements in PROs (patient reported outcomes) will be enough to tip the scales in favor on an Enclomiphene approval.
  • Anyone know why this jumped after hours?
  • Repros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
    THE WOODLANDS, Texas, May 17, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) ("Repros" or the "Company") today announced that it intends to offer primary shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Repros intends to use the net proceeds from the offering for general corporate purposes.

    Laidlaw & Company (UK) Ltd. is the sole book-running manager for the offering.

    A shelf registration statement on Form S-3 relating to the securities was filed with the Securities and Exchange Commission and is effective. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement relating to the offering, when available, may be obtained from the offices of Laidlaw & Company (UK) Ltd., 546 Fifth Avenue, 5th Floor, New York, NY, 10036, telephone: 212-953-4900 or by email at syndicate@laidlawltd.com.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

  • New Q1 institutional numbers are out and Rprx percentage increased overall by 507,691 shares. Blackrock Inc is back with 771,287 shares.
  • Lost my money on this junk stock
  • RPRX meeting with FDA to see if they will accept their liver toxicity studies for Proellex and if not this will be $.01 anyone agree its worth that kind of risk right now? i sold i think this is garbage abd hiwatt tge biggest scam artist as he shorts while he gets you to buy...don't believe me/ Hes bashing all over the place just check out LPCN all he does is bash the stock,,he is obvious and untrustworthy hedgie...suckering you to buy RPRX so he cam short more and LPCN holders to sell....why? figure that out....lol...
  • Joe P was right!

    Increasing evidence suggests that in many middle-aged and older men low testosterone is due to functional HPT axis suppression. The nonspecific androgen deficiency-like symptoms may, at least in part, be mediated by comorbidities. Knowledge that obesity and comorbidities might be causing symptoms and why testosterone levels are low may motivate some men to more actively engage in lifestyle interventions. Although dedicated studies to assess the efficacy of lifestyle measures, such as weight loss, and optimization of comorbidities among stringently selected symptomatic men with low testosterone levels are lacking, the current evidence supports these measures as first-line management approaches, as they have the potential to improve androgen deficiency–like symptoms irrespective of their effect on testosterone levels, reverse the HPT axis suppression to a degree sufficient to normalize the often only modestly reduced testosterone levels, and improve overall health. Thus, these interventions may have demonstrable health benefits beyond the potential for increasing testosterone levels. These measures should be accompanied by evidence-based treatment targeting the main clinical problem (e.g., erectile dysfunction or osteoporosis).
    However, lifestyle intervention, management of comorbid illnesses, and discontinuation of offending medications may be difficult and many times not possible. For example, substantial weight loss in obese men is required to achieve meaningful increases in testosterone levels. Even if successful, such measures may be insufficient to relieve symptoms and to normalize testosterone levels. In appropriately selected men, in the context of this holistic approach encompassing treatment of the underlying causes of functional HPT axis suppression and of symptoms, testosterone treatment could be started concomitantly or after these initial measures fail. In contrast, the use of other medications intended to increase testosterone levels cannot currently be recommended outside of clinical trials due to lack of evidence.
  • Well, well, the medical community may finally be coming around to the way of thinking that Old Joe P. was preaching, and that is that older, obese men with secondary hypo might have reversible condition when provided with diet and exercise and the correct medication. Although they mention the use of SERMs, they won't recommend them specifically because of lack of trial data, Hopefully the new benefit study that just finished will shed more light on the topic. Here are a couple clips from a new 13 page article just published on Medpage.
    Context: Middle-aged and older men (≥50 years), especially those who are obese and suffer from comorbidities, not uncommonly present with clinical features consistent with androgen deficiency and modestly reduced testosterone levels. Commonly, such men do not demonstrate anatomical hypothalamic–pituitary–testicular axis pathology but have functional hypogonadism that is potentially reversible.
    Evidence Acquisition: Literature review from 1970 to October 2016.
    Evidence Synthesis: Although definitive randomized controlled trials are lacking, evidence suggests that in such men, lifestyle measures to achieve weight loss and optimization of comorbidities, including discontinuation of offending medications, lead to clinical improvement and a modest increase in testosterone. Also, androgen deficiency–like symptoms and end-organ deficits respond to targeted treatments (such as phosphodiesterase-5 inhibitors for erectile dysfunction) without evidence that hypogonadal men are refractory. Unfortunately, lifestyle interventions remain difficult and may be insufficient even if successful. Testosterone therapy should be considered primarily for men who have significant clinical features of androgen deficiency and unequivocally low testosterone levels. Testosterone should be initiated either concomitantly with a trial of lifestyle measures, or after such a trial fails, after a tailored diagnostic work-up, exclusion of contraindications, and appropriate counseling.
    Conclusions: There is modest evidence that functional hypogonadism responds to lifestyle measures and optimization of comorbidities. If achievable, these interventions may have demonstrable health benefits beyond the potential for increasing testosterone levels. Therefore, treatment of underlying causes of functional hypogonadism and of symptoms should be used either as an initial or adjunctive approach to testosterone therapy.
  • Hiwatt how is that 300% share increase you made going that you paid in the $.80's for? you are such a schill and obvious employee or maybe Joe P himself....l....o....s.....e......r......
  • HIwatt its pretty obvious you work for RPRX you always twist terrible news into something geat coming...how much do they pay you? 3M shares?
  • LOOKS LIKE A REVERSE STOCK SPLIT COMING AFTER DELISTING, IMO. European Union is not going to allow a drug with data done on Cuban gay men? where did RPRX come up with that idea. thats no way to see if that 'sub group' imo, actually experienced more sexual events vs more sexual partners...LMFAO...i'll be surprised if this stock can hold $.25 cents anyone wonder why the CEO Joe P resigned? just google ZONA and then Zonagen he tried tha msae thing back in '98 trying to compete with Viagra but Znagen was a FDA reject..stock went from $20's to $20 cents just like hapenning again...imo and Proellex? anyone see the liver toxicity concerns? google for yourself its all there. Right hiwatt?
  • $2.5m equals 3 months of breathing room. Fda response on Proellex and EU update.
  • what do expect to happen when you do an offferi invester wil dump dump tmassemassese sellingmping dumping of shares coming crhingbelow 40 cent yu you ben warned getoutouthe exit exit door be very very afraid to loss a lotlot moremoney crashjing below 40 cent you been warned
  • Next 2 weeks for Rprx
    1- Meeting with FDA to submit liver toxicity results for Proellex.
    2- Answers submitted to day 120 questions in EU & clock restart
    3 Completion of 15 Enclomiphene benefit study
    4- Q1 results- Hope to hear from new CEO at conference call
  • Nice call Hiwatt (NOT) you have been pumping this stock daily since at least $12.50 when i started reading them......and you seem to be living on the LPCN board 24/7 bashing non stop......gee anyone here want to look at a stock that hiwatt is not long in...LMFAO!!!! Zacks gives LPCN a $9 PPS guidance and only $3's now.... thanks Hiwatt you are completely useless i think everyone here will agree, or you work for RPRX which i would guarantee is the case...imo
  • Like watching paint dry, times 10,000
  • Hmmm, according to Zacks latest article, Enclomiphene was approved for overweight low T men in the EU in 2016. How did I miss this? Must have been asleep at the wheel.

    The most advanced candidate in Repros’ pipeline is enclomiphene, which is currently under review in the EU. The company intends to get the candidate approved for the treatment of secondary hypogonadism. A decision on the approval status of the candidate should be out in 2017.

    Moreover, Repros is evaluating enclomiphene for the treatment of low testosterone level in overweight men. The drug was approved in the EU in 2016 for this indication while the phase II study data is under review in the U.S.
  • been trending down for the last nine months.
    I'll buy in @ .65 - .70 should be turning around by then
  • RPRX has turned into a disaster i am out.... was in this stock since 2010.
  • This the second Dr. I've heard from that has worked on clinical trials for uterine fibroid. Both were very excited about having a possible oral solution. Although this article pertains to Allergan's Esmya and not Proellex,that's because Rprx is the redheaded stepchild.
    If uterine fibroids will affect more than 80 percent of women in the United States by the time they are 50 years old, then why has such little research been done about the gynecological disorder? What should you know about uterine fibroids and uterine fibroid treatment? Well, for one, thanks to the research done by scientists at the global pharmaceutical company, Allergan, those who suffer from uterine fibroids may finally have a treatment option that only requires that they take a pill rather than undergo invasive and expensive surgery to treat these benign tumors in and/or around the wall of the uterus, which can cause pain, abnormal bleeding, and fertility problems.

    I spoke to Dr. Ayman Al-Hendy, a professor and gynecologist at Georgia Regents University and one of the researchers working on this new oral medication in clinical trials known as Venus I at Allergan. "This is an exciting time," Dr. Al-Hendy tells Bustle. "Allergan has been committed to developing new treatments for women's health. Most treatment options for women are invasive procedures involving major surgery... But with these new results from the Venus I clinical trials, we are going in the right direction toward getting approval for the first oral treatment [for uterine fibroids]."

    The invasive surgeries of which Dr. Al-Hendy speaks are hysterectomies (complete removal of the uterus) and myomectomies (removal of the tumors). One-third of all hysterectomies are performed to treat uterine fibroids, which works out to over 200,000 hysterectomies per year. Hundreds of thousands of women, from the ages of 15 to 54, are hospitalized yearly due to uterine fibroids. It is expected that if new treatment methods are not developed and population growth continues, then there will be a 31 percent increase in uterine-fibroid related hysterectomies by 2050.

    157 patients, all women between the ages of 18-50, participated in the Venus I clinical trials. Researchers were evaluating the ability of the compound ulipristal acetate which, as stated in a press release from Allergan, "[decreases] the formation of new fibroid cells and [promotes] fibroid cell death." Dr. Al-Hendy says, "This study was looking at the ability of this compound to control symptoms of uterine fibroids – especially abnormal vaginal bleeding. We have found that it is fairly effective at controlling bleeding. Specifically, in 60 percent of women, it stopped the bleeding. And that is the main pressing symptom from fibroids."

    It is frighteningly common for gynecological health issues and women's health issues in general to be dismissed as "complex" and "outside the norm".
    When a disorder is as common and as disruptive as uterine fibroids, it seems pretty reasonable to assume that the medical community would study effective treatment methods. But that's not the case. Harvard Health Publications states, "There are only a few randomized trials to guide treatment." It is frighteningly common for gynecological health issues and women's health issues in general to be dismissed as "complex" and "outside the norm" (it is a "special issue" because it is not a "men's issue") — but anything that happens to 80 percent of women seems like a pretty "normal" occurrence to me.

    Other parts of the world, specifically Europe and Canada, already provide oral medication containing ulipristal acetate to women suffering from painful uterine fibroids, but the Venus I clinical trials are the first to research ulipristal acetate here in the States. The only uterine fibroids medication that is currently on the market in the U.S., explains Dr. Al-Hendy, is an injection that contains a compound called leuprolide acetate. This compound works by lessening production of the primary female sex hormone, estradiol. Says Dr. Al-Hendy, "Because leuprolide acetate reduces estradiol, the injection causes a temporary chemically-induced menopausal state," or pre-menopause. Due to this side effect, Dr. Al-Hendy says women with uterine fibroids are not advised to use the injection for more than three months. It can only provide temporary relief and is often used by patients in preparation for fibroids surgery.

    Dr. Al-Hendy says that this side effect has not been present in the Venus I clinical trials of ulipristal acetate. "[These] pills taken by the mouth ... have the potential to offer the first long term treatment option for women suffering from uterine fibroids in the U.S. Menopause is not a side-effect of this option."

    And the potential of this drug is a long-time coming. "For me, as a gynecologist who treats many patients for fibroids... we have been waiting for this for years. It is an exciting time for both patients and the practitioners who serve these women," Dr. Al-Hendy says.